MediVector, Inc.   Report issue

For profit Phase 3
Founded: Boston MA United States (1998)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2013
NCT02008344
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

favipiravir (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Influenza, Human (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1